Quantum Biopharma Ltd. (QNTM)

Pharmaceutical Preparations · market cap $25M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-06 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Quantum Biopharma Ltd. (QNTM) is a micro-cap pharmaceutical company with a market cap of approximately $23M and a share price near $3.37. Its lead asset, Firibastat, is in Phase 3 development for hypertension, accompanied by QGC001 (Phase 2, Essential Hypertension) and Ramipril (Phase 2, Myocardial Infarction). The nearest disclosed catalyst is an August 5, 2026 earnings release.

The catalyst path

2026-11-06 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Firibastat	Phase 3	Hypertension
QGC001	Phase 2	Essential Hypertension
Ramipril	Phase 2	Myocardial Infarction

Price & technical context

3-month

-16.9%

6-month

-8.8%

12-month

-81.6%

52-wk range

$2.10–$15.99

vs 50-day MA

-16.9%

vs 200-day MA

-32.9%

Realized vol

134.4%

Max drawdown

-94.0%

Daily closes through 2026-10-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for QNTM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.